Jinoos Yazdany, MD, MPH


Dr. Yazdany is Chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital (ZSFG) and the Alice Betts Endowed Professor of Medicine at UCSF. She received her undergraduate degree from Stanford, her MD from UCLA, and her MPH from Harvard. She joined the faculty after completing internal medicine residency and fellowship in rheumatology at UCSF. As a rheumatologist specializing in systemic lupus, she practices at ZSFG and co-directs the UCSF Health Lupus Clinic.

Dr. Yazdany’s scholarship focuses on improving health care quality, safety and outcomes for individuals with chronic rheumatic diseases. She co-directs the UCSF Rheumatology Quality and Informatics Lab, an interdisciplinary group that uses health services research, informatics, and implementation science to inform national health care improvement initiatives. She has worked with colleagues to develop the American College of Rheumatology’s RISE registry that aggregates and analyzes data from rheumatology practices around the country to inform quality improvement and research projects. She has developed a number of quality measures that have been endorsed by the National Quality Forum and are being used in federal programs. She has served as PI of grants from the NIH/NIAMS, AHRQ, and CDC and is the recipient of a NIAMS K24 mentoring award. Dr. Yazdany also serves as co-director of a research core – one focused on human subjects recruitment and clinical informatics support – for the NIH/NIAMS-funded P30 UCSF PREMIER Center.

Nationally, Dr. Yazdany has held numerous leadership positions, including serving as co-chair of the ACR’s Quality Measures Subcommittee, chair of the ACR’s Registries and Health IT Committee, chair of Research and Publications for the RISE registry, and member of the NQF’s Health Professional Council. She has earned several honors and awards for her work, including the Mary Betty Stevens Young Investigator Prize from the Lupus Foundation of America, the Ephraim Engleman Award for Arthritis Research, and the Hulda Irene Duggan Arthritis Investigator Award from the Arthritis Foundation.
M.D., 2000 - School of Medicine, University of California Los Angeles
Residency, - Internal Medicine, University of California, San Francisco
  1. Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
  2. Quality of care for patients with SLE: data from the American College of Rheumatology's RISE registry.
  3. Rheumatology Informatics System for Effectiveness (RISE) Practices See Significant Gains in Rheumatoid Arthritis Quality Measures.
  4. Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus.
  5. Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported re
  6. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases.
  7. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis.
  8. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice.
  9. COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the C
  10. Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results from the California Lupus Epidemiology Study.
  11. The impact of limited health literacy on patient-reported outcomes in systemic lupus erythematosus.
  12. Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment.
  13. COVID-19 in Rheumatic Diseases: A Research Agenda.
  14. Conducting research in a pandemic: The power of social media.
  15. Reweighting to address nonparticipation and missing data bias in a longitudinal electronic health record study.
  16. Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al.
  17. Mortality among Hospitalized Individuals with Systemic Lupus Erythematosus in the United States between 2006 and 2016.
  18. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic.
  19. The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance.
  20. Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical cou
  21. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
  22. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
  23. A Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessments Measures in Rheumatoid Arthritis.
  24. Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Healthcare Settings.
  25. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
  26. Racial/Ethnic Differences in Prevalence of and Time to Onset of SLE Manifestations: The California Lupus Surveillance Project (CLSP).
  27. Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States.
  28. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.
  29. Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes.
  30. Patient and clinician perspectives on a patient-facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis.
  31. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus.
  32. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
  33. RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.
  34. Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  35. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
  36. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
  37. Using process improvement and systems redesign to improve rheumatology care quality in a safety net clinic.
  38. Reimagining Rheumatology: Big Data and the Future of Clinical Practice and Research.
  39. Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study.
  40. Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus.
  41. 2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis.
  42. Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.
  43. Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review.
  44. Development of a Set of Lupus-Specific Ambulatory Care Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.
  45. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  46. Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis.
  47. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.
  48. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.
  49. Using Health Information Technology to Support Use of Patient-Reported Outcomes in Rheumatology.
  50. Differences in Longitudinal Disease Activity Between Research Cohort and Noncohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data.
  51. Reply.
  52. Increased Risk of Ischemic Stroke in Systemic Sclerosis: A National Cohort Study of US Veterans.
  53. Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis.
  54. Quality improvement initiatives in rheumatology: an integrative review of the last 5 years.
  55. Poverty, Neighborhoods, Persistent Stress, and Systemic Lupus Erythematosus Outcomes: A Qualitative Study of the Patients' Perspective.
  56. Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.
  57. Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling.
  58. Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus.
  59. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study.
  60. Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates.
  61. Editorial: The Evolving Art and Science of American College of Rheumatology Guidelines.
  62. Does Systemic Lupus Erythematosus Care Provided in a Lupus Clinic Result in Higher Quality of Care Than That Provided in a General Rheumatology Clinic?
  63. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
  64. Accurate Measurement In California's Safety-Net Health Systems Has Gaps And Barriers.
  65. Further Lessons in Pneumocystis Pneumonia Prophylaxis.
  66. Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data.
  67. "Am I OK?" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes.
  68. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
  69. Patient-reported outcome measures for use in clinical trials of SLE: a review.
  70. Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study.
  71. Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus.
  72. Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis.
  73. Improving Patient Safety in Public Hospitals: Developing Standard Measures to Track Medical Errors and Process Breakdowns.
  74. Sex Differences in Health Care Utilization, End-Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis.
  75. Correction to: Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
  76. The impact of smoking on disease measures in rheumatoid arthritis: the need for appropriate adjustment of time-varying confounding.
  77. Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis.
  78. Leveraging the electronic health record to improve quality and safety in rheumatology.
  79. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
  80. A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus.
  81. Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus.
  82. Variations in Radiographic Procedure Use for Medicare Patients With Rheumatoid Arthritis.
  83. Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease.
  84. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
  85. A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries.
  86. Reply.
  87. Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.
  88. Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population.
  89. Is frailty a relevant concept in SLE?
  90. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
  91. Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate.
  92. Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context.
  93. Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement.
  94. Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures.
  95. Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study.
  96. American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology.
  97. Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures.
  98. Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic.
  99. Poverty, Depression, or Lost in Translation? Ethnic and Language Variation in Patient-Reported Outcomes in Rheumatoid Arthritis.
  100. Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement in Rheumatology.
  101. National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia.
  102. Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.
  103. Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making.
  104. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
  105. Applying Choosing Wisely: Antinuclear Antibody (ANA) and Sub-Serology Testing in a Safety Net Hospital System.
  106. Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis.
  107. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
  108. Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safety-Net Health Setting.
  109. Muscle Strength and Changes in Physical Function in Women With Systemic Lupus Erythematosus.
  110. Factors associated with access to rheumatologists for Medicare patients.
  111. Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication.
  112. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique.
  113. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus.
  114. Revisit rates and associated costs after an emergency department encounter: a multistate analysis.
  115. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
  116. A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.
  117. Interactions between patients, providers, and health systems and technical quality of care.
  118. Using medicare data to understand health care value--reply.
  119. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus.
  120. Muscle strength, muscle mass, and physical disability in women with systemic lupus erythematosus.
  121. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
  122. Thirty-day hospital readmissions in systemic lupus erythematosus: predictors and hospital- and state-level variation.
  123. Using Medicare data to understand low-value health care: the case of intra-articular hyaluronic acid injections.
  124. Application and feasibility of systemic lupus erythematosus reproductive health care quality indicators at a public urban rheumatology clinic.
  125. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.
  126. Longitudinal validation of the Brief Index of Lupus Damage.
  127. Challenges in understanding the role of pregnancy morbidity in cardiovascular risk in SLE.
  128. Post-marketing experiences with belimumab in the treatment of SLE patients.
  129. Validity of a self-administered version of the brief index of lupus damage in a predominantly African American systemic lupus erythematosus cohort.
  130. Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup.
  131. Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States.
  132. Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study.
  133. A168: systemic lupus erythematosus in-hospital mortality risk across ages: a national estimate.
  134. Rheumatoid arthritis quality measures and radiographic progression.
  135. Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.
  136. Measuring hospital quality using pediatric readmission and revisit rates.
  137. Reply: To PMID 22556106.
  138. Underestimation of the reliability of codes for rheumatoid arthritis within administrative data: comment on the article by Ng et al.
  139. Clinical problem-solving. The heart of the matter.
  140. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.
  141. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients.
  142. Sex differences in assessment of obesity in rheumatoid arthritis.
  143. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.
  144. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus.
  145. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
  146. Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care.
  147. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
  148. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus.
  149. Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus.
  150. Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know.
  151. Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus.
  152. Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study.
  153. Association of Sweet's Syndrome and Systemic Lupus Erythematosus.
  154. Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnair
  155. Impact of obesity on functioning among women with systemic lupus erythematosus.
  156. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus.
  157. Using the Center for Epidemiologic Studies Depression Scale to screen for depression in systemic lupus erythematosus.
  158. Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.
  159. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.
  160. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus.
  161. Defining quality of care in rheumatology: the American College of Rheumatology white paper on quality measurement.
  162. Systematic review of the literature informing the systemic lupus erythematosus indicators project: reproductive health care quality indicators.
  163. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?
  164. Drug monitoring in systemic lupus erythematosus: a systematic review.
  165. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.
  166. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators.
  167. Role of community and individual characteristics in physician visits for persons with systemic lupus erythematosus.
  168. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study.
  169. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?
  170. Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators.
  171. Frequent use of the emergency department among persons with systemic lupus erythematosus.
  172. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.
  173. Health-related quality of life and employment among persons with systemic lupus erythematosus.
  174. Bone health in systemic lupus erythematosus.
  175. Clinical practice guidelines and diagnostic uncertainty in the management of early rheumatoid arthritis.
  176. A quality indicator set for systemic lupus erythematosus.
  177. Depression, medication adherence, and service utilization in systemic lupus erythematosus.
  178. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample.
  179. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.
  180. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus.
  181. Comment on "Quality indicators for psoriatic arthritis".
  182. Valued life activity disability played a significant role in self-rated health among adults with chronic health conditions.
  183. The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus.
  184. Disability in valued life activities among individuals with systemic lupus erythematosus.
  185. Quality of care in the rheumatic diseases: current status and future directions.
  186. Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort.
  187. Impact of memory impairment on employment status in persons with systemic lupus erythematosus.
  188. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus.
  189. Medicaid and access to care among persons with systemic lupus erythematosus.
  190. Impact of health maintenance organizations and fee-for-service on health care utilization among people with systemic lupus erythematosus.
  191. Six refractory lupus patients treated with rituximab: a case series.
  192. Work dynamics among persons with systemic lupus erythematosus.
  193. The role of CD40 ligand in systemic lupus erythematosus.
  194. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.